Brookline raised the firm’s price target on Lisata Therapeutics (LSTA) to $32 from $20 and keeps a Buy rating on the shares. The firm cites extended patent protection for the target increase after Lisata received a new patent for certepetide through March 2040.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics Secures U.S. Patent for Certepetide
- Lisata Therapeutics Reveals Promising Phase 2 Trial Data
- Lisata Therapeutics announces preliminary cohort B results from ASCEND trial
- Strategic Collaboration with GATC Health Boosts Lisata Therapeutics’ Growth Potential
- Lisata Therapeutics Advances Certepetide for Cancer Treatment